PDF(Pubmed)
Abstract：
Objective- To acknowledge patient-perceived voice-related and overall quality of life (QOL) in addition to disability index based on the validated voice-related quality of life survey (VRQOL), WHOQOL-BREF, and WHO DAS II questionnaires in T2 and early T3 laryngeal tumors after definitive radiotherapy. Methods- 35 patients of T2(15) and early T3(20) tumors were enrolled, assessed with three questionnaires of VRQOL, WHOQOL-BREF, and WHO DAS II before the start of radiotherapy, then at 12 and 24 weeks after radiotherapy, and the results were analyzed. Results- All 35 (100%) patients had significant vocal deterioration with a raw VRQOL score of more than 25 at the beginning, which significantly improved at 12 weeks post-radiotherapy (p < 0.5). However, VRQOL scores at the 12th and 24th weeks were statistically insignificant. On comparing the WHOQOL-BREF and WHO DAS II, domains of physical health, psychological health, and participation in society showed significant improvement in both the groups after radiotherapy except distress scores in T2 laryngeal cancers, where pre and post-radiotherapy scores were not significantly different suggesting residual distress. Conclusion- The QOL parameters improve significantly with treatment, however, there exists a persistence of residual distress even at 24 weeks after radiotherapy and hence, routine involvement of clinical psychologists should be emphasized in practice to alleviate anxiety, distress, and concerns regarding disease outcome and recurrence. 12 to 24 weeks post-radiotherapy can be an optimum time to gauge the improvement in the patient-related QOL outcome parameters and does not differ much between these durations.
UNASSIGNED: The online version contains supplementary material available at 10.1007/s12070-022-03397-3.
UNASSIGNED: The online version contains supplementary material available at 10.1007/s12070-022-03397-3.
摘要：
目标-确认患者感知的语音相关和总体生活质量（QOL），以及基于已验证的语音相关生活质量调查（VRQOL）的残疾指数，WHOQOL-BREF,明确放疗后T2和T3早期喉肿瘤的WHODASII问卷。方法选择35例T2(15)和T3(20)早期肿瘤患者,用三份VRQOL问卷进行评估，WHOQOL-BREF,和WHODASII在放疗开始之前，然后在放疗后12周和24周，并对结果进行了分析。结果-所有35（100％）患者在开始时的原始VRQOL评分超过25，放疗后12周显着改善（p<0.5）。然而,第12周和第24周的VRQOL评分无统计学意义。在比较WHOQOL-BREF和WHODASII时，身体健康领域，心理健康,和社会参与显示两组放疗后的显着改善，除了T2喉癌的痛苦评分，其中放疗前和放疗后评分没有显着差异，提示残余窘迫。结论-QOL参数随着治疗而明显改善，然而,即使在放疗后24周，仍然存在残留的痛苦，因此，在实践中应强调临床心理学家的常规参与，以缓解焦虑，苦恼,以及对疾病结果和复发的担忧。放疗后12至24周可以是衡量患者相关QOL结果参数改善的最佳时间，并且在这些持续时间之间没有太大差异。
■在线版本包含补充材料，可在10.1007/s12070-022-03397-3获得。
■在线版本包含补充材料，可在10.1007/s12070-022-03397-3获得。
